GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

With antibiotic-resistant gonorrhea on the rise, the vaccine could provide a way to prevent the disease from spreading.

Stocks from pharmaceutical companies and healthcare spaces dominated analysts' choices for Thursday's trading session.

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as ...

This Philly-based company is using AI to predict which medical research can lead to profitable drugs and therapies Clarivate ...

Tezepelumab, a monoclonal antibody targeting TSLP approved for add-on severe asthma treatment in 2021, had been associated ...

Microsoft launches Discovery, its new enterprise AI platform from Build 2025, set to accelerate scientific R&D via collaborative AI agents & a graph-knowledge engine for faster innovation.

Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter at the ...

Microsoft launches Discovery platform that uses agentic AI to compress years of scientific research into days, transforming R ...